Michael Martin is the Global Head of Takeda Ventures, Inc. (TVI) and is based in San Diego, California. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and development of 17 innovative investigational drugs and 4 commercial products. Prior to joining TVI, Michael was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for sourcing and transacting technologies and early-stage pipeline programs. He has held executive and scientific roles with Intellikine (acquired by Takeda), TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals and Monsanto Corporation. Michael earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.